


Patient Information		GEISINGER MEDICAL LABORATORIES
Name: TESTING, PROSTATE J DOB (AGE) Sex: 6/13/1965 (42) M MRN (Client MRN): 654321		
Billing #: 5464721781 Order #:		
Client Information	Specimen Information	
Location: F1A Copy To: Outside Client.:	Collected Date: 1/14/2008 Accession Date: 1/14/2008 Reported Date: 1/15/2008 Submitting: 83420 - Jennifer Simmons, MD	Accession #: S08-9 Client Case #: Report Type: Final Report

Diagnosis

Status: ***Electronically Signed Out*** Pathologist: Myra Wilkerson, M.D. - GWV Lab



Part Location	Core (mm)	Diagnosis	Gleas on	pCA (mm)	%pCA
A Left Lateral Base	19	Benign	0	0	--%
B Left Base	22	Benign	0	0	--%
C Midline Base	10	Benign	0	0	--%
D Right Base	12	Benign	0	0	--%
E Right Lateral Base	15	Benign	0	0	--%
F Left Lateral Mid	20	Benign	0	0	--%
G Left Mid	16	Benign	0	0	--%
H Right Mid	16	Benign	0	0	--%
I Right Lateral Mid	19	Benign	0	0	--%
J Left Lateral Apex	17	Benign	0	0	--%
K Left Apex	15	Benign	0	0	--%
L Right Apex	16	Adenocarcinoma	3+3=6	1	6%
M Right Lateral Apex	13	Benign	0	0	--%
Overall Total	209			1 mm	0.5%

*pCA = Prostate Carcinoma

Clinical History

Pre-op Diagnosis: Elevated PSA.

Microscopic Findings

A-K, M: Three levels through each of the core biopsies of prostate gland are examined. No neoplastic acini are identified. Active and chronic inflammation are present in specimens B, D, E, and G.

L: Three levels through the core biopsy of the prostate gland tissue are examined. There is a focus of adenocarcinoma, moderately well differentiated (please refer to synoptic data). An immunoperoxidase stain for CK903 demonstrates lack of a basal cell layer around these acini.

This case was reviewed for intradepartmental quality assurance.

A: 88305,88342IMMUNOP(3); B: 88305; C: 88305; D: 88305; E: 88305; F: 88305; G: 88305; H: 88305; I: 88305; J: 88305; K: 88305; L: 88305; M: 88305

Photographic images and diagrams represent key findings in this case; they are not intended to replace a complete review of the final diagnostic report.

The following applies to all Immunohistochemistry, Direct Immunofluorescence, & Chromogenic In situ Hybridization Assays: This testing was developed and its performance characteristics determined by Geisinger Medical Laboratories as required by CLIA '88 regulations. Although not approved for clinical use by the U.S. FDA, they have determined that such approval is unnecessary.